https://scholars.lib.ntu.edu.tw/handle/123456789/551222
標題: | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | 作者: | Yen C.-J. Kiyota N. Hanai N. Takahashi S. Yokota T. Iwae S. Shimizu Y. RUEY-LONG HONG Goto M. Kang J.-H. Li W.S.K. Ferris R.L. Gillison M. Endo T. Jayaprakash V. Tahara M. |
關鍵字: | Asian population; clinical trial; immunotherapy; nivolumab; squamous cell carcinoma of the head and neck | 公開日期: | 2020 | 出版社: | John Wiley and Sons Inc. | 卷: | 42 | 期: | 10 | 起(迄)頁: | 2852-2862 | 來源出版物: | Head and Neck | 摘要: | Background: The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. Methods: The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolumab group: 23 patients; investigator's choice of therapy [IC] group: 11 patients) were analyzed. Results: The median overall survival (OS) was 12.1 and 6.2 months for the nivolumab and IC groups, respectively. The estimated 2-year OS rates were 22.7% and 0% for the nivolumab and IC groups, respectively. In the nivolumab group, the patients with any treatment-related adverse events (TRAEs), including skin-related disorders, showed better OS than the patients without any TRAEs. Conclusions: Nivolumab demonstrated prolonged OS benefits in the Asian population with platinum-refractory R/M SCCHN and a favorable safety profile. TRAEs, including skin-related disorders, may be favorable prognostic factors for nivolumab efficacy. Clinical trial registration: NCT02105636. ? 2020 The Authors. Head & Neck published by Wiley Periodicals LLC. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087145277&doi=10.1002%2fhed.26331&partnerID=40&md5=5a39b19dc05b9b84ed3069571de76b52 https://scholars.lib.ntu.edu.tw/handle/123456789/551222 |
ISSN: | 1043-3074 | DOI: | 10.1002/hed.26331 | SDG/關鍵字: | cetuximab; docetaxel; methotrexate; nivolumab; adverse outcome; aged; Article; Asian; cancer patient; cancer recurrence; clinical article; controlled study; decreased appetite; diarrhea; drug choice; drug dose increase; drug dose reduction; drug efficacy; drug safety; endocrine disease; fatigue; female; follow up; gastrointestinal disease; head and neck squamous cell carcinoma; human; hypersensitivity; hypothyroidism; maculopapular rash; male; nausea; open study; overall survival; phase 3 clinical trial; priority journal; pruritus; randomized controlled trial; rash; skin disease; stomatitis; survival rate |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。